Holly A. Bina

4.4k total citations · 2 hit papers
16 papers, 3.7k citations indexed

About

Holly A. Bina is a scholar working on Molecular Biology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Holly A. Bina has authored 16 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 4 papers in Immunology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Holly A. Bina's work include Fibroblast Growth Factor Research (11 papers), Kruppel-like factors research (10 papers) and Epigenetics and DNA Methylation (10 papers). Holly A. Bina is often cited by papers focused on Fibroblast Growth Factor Research (11 papers), Kruppel-like factors research (10 papers) and Epigenetics and DNA Methylation (10 papers). Holly A. Bina collaborates with scholars based in United States, Sweden and Spain. Holly A. Bina's co-authors include Alexei Kharitonenkov, James D. Dunbar, Tamer Coşkun, M. Schneider, Jeffrey S. Flier, Ffolliott M. Fisher, Eleftheria Maratos–Flier, Patrick J. Antonellis, Yanyun Chen and David E. Moller and has published in prestigious journals such as PLoS ONE, Cell Metabolism and Diabetes.

In The Last Decade

Holly A. Bina

16 papers receiving 3.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fibroblast Growth Factor 21 Corrects Obesity in Mice

2008 890 citations Tamer Coşkun, Holly A. Bina et al. Endocrinology profile →
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State

2010 666 citations Ffolliott M. Fisher, Patricia C. Chui et al. Diabetes profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Holly A. Bina United States	16	2.9k	699	492	375	344	16	3.7k
Jun Nakura Japan	25	1.9k 0.6×	512 0.7×	292 0.6×	208 0.6×	506 1.5×	71	3.2k
Γεώργιος Κούκος United States	21	1.5k 0.5×	361 0.5×	344 0.7×	358 1.0×	290 0.8×	31	2.4k
Serkan Kır Türkiye	16	1.4k 0.5×	950 1.4×	792 1.6×	434 1.2×	164 0.5×	24	2.8k
Henian Cao Canada	36	2.2k 0.7×	542 0.8×	360 0.7×	938 2.5×	790 2.3×	70	3.8k
Rosa Di Paola Italy	21	682 0.2×	538 0.8×	641 1.3×	208 0.6×	282 0.8×	64	1.8k
Katsuhiko Asanuma Japan	29	1.5k 0.5×	284 0.4×	392 0.8×	325 0.9×	668 1.9×	89	4.0k
Anna Gumà Spain	31	1.4k 0.5×	849 1.2×	268 0.5×	667 1.8×	109 0.3×	74	2.8k
Marc Délepine France	21	1.5k 0.5×	505 0.7×	403 0.8×	859 2.3×	1.1k 3.1×	28	3.2k
Sabrina Prudente Italy	24	825 0.3×	372 0.5×	284 0.6×	393 1.0×	349 1.0×	69	1.8k
Tatiyana L. Shiyanova United States	8	1.6k 0.6×	392 0.6×	315 0.6×	250 0.7×	219 0.6×	9	2.0k

Countries citing papers authored by Holly A. Bina

Since Specialization

Citations

This map shows the geographic impact of Holly A. Bina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holly A. Bina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holly A. Bina more than expected).

Fields of papers citing papers by Holly A. Bina

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Holly A. Bina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holly A. Bina. The network helps show where Holly A. Bina may publish in the future.

Co-authorship network of co-authors of Holly A. Bina

This figure shows the co-authorship network connecting the top 25 collaborators of Holly A. Bina. A scholar is included among the top collaborators of Holly A. Bina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Holly A. Bina. Holly A. Bina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Benschop, Robert J., Chi-Kin Chow, Yu Tian, et al.. (2019). Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. mAbs. 11(6). 1175–1190. 34 indexed citations

Ting, Joey, Stephen Antonysamy, Stephen R. Wasserman, et al.. (2018). Utilization of peptide phage display to investigate hotspots on IL-17A and what it means for drug discovery. PLoS ONE. 13(1). e0190850–e0190850. 21 indexed citations

Liu, Ling, Kristine Kikly, Jirong Lu, et al.. (2016). Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. Journal of Inflammation Research. 9. 39–39. 172 indexed citations

Kikly, Kristine, Joseph Manetta, Holly A. Bina, et al.. (2014). Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. Journal of Inflammation Research. 7. 121–121. 39 indexed citations

Lundberg, Jon O., Charlotte Höybye, Holly A. Bina, et al.. (2013). Influence of growth hormone on circulating fibroblast growth factor 21 levels in humans. Journal of Internal Medicine. 274(3). 227–232. 20 indexed citations

Adams, Andrew C., Tamer Coşkun, M. Schneider, et al.. (2012). Fundamentals of FGF19 & FGF21 Action In Vitro and In Vivo. PLoS ONE. 7(5). e38438–e38438. 101 indexed citations

Feingold, Kenneth R., Carl Grünfeld, Josef G. Heuer, et al.. (2012). FGF21 Is Increased by Inflammatory Stimuli and Protects Leptin-Deficient ob/ob Mice from the Toxicity of Sepsis. Endocrinology. 153(6). 2689–2700. 110 indexed citations

Fisher, Ffolliott M., Jennifer L. Estall, Andrew C. Adams, et al.. (2011). Integrated Regulation of Hepatic Metabolism by Fibroblast Growth Factor 21 (FGF21) in Vivo. Endocrinology. 152(8). 2996–3004. 198 indexed citations

Fisher, Ffolliott M., Patricia C. Chui, Patrick J. Antonellis, et al.. (2010). Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State. Diabetes. 59(11). 2781–2789. 666 indexed citations breakdown →

10.

Berglund, Eric D., Candice Y. Li, Holly A. Bina, et al.. (2009). Fibroblast Growth Factor 21 Controls Glycemia via Regulation of Hepatic Glucose Flux and Insulin Sensitivity. Endocrinology. 150(9). 4084–4093. 244 indexed citations

11.

Izumiya, Yasuhiro, Holly A. Bina, Noriyuki Ouchi, et al.. (2008). FGF21 is an Akt‐regulated myokine. FEBS Letters. 582(27). 3805–3810. 345 indexed citations

12.

Gälman, Cecilia, Alexei Kharitonenkov, Holly A. Bina, et al.. (2008). The Circulating Metabolic Regulator FGF21 Is Induced by Prolonged Fasting and PPARα Activation in Man. Cell Metabolism. 8(2). 169–174. 429 indexed citations

13.

Micanovic, Radmila, James D. Dunbar, David A. Driver, et al.. (2008). Different roles of N‐ and C‐ termini in the functional activity of FGF21. Journal of Cellular Physiology. 219(2). 227–234. 108 indexed citations

14.

Coşkun, Tamer, Holly A. Bina, M. Schneider, et al.. (2008). Fibroblast Growth Factor 21 Corrects Obesity in Mice. Endocrinology. 149(12). 6018–6027. 890 indexed citations breakdown →

15.

Kharitonenkov, Alexei, James D. Dunbar, Holly A. Bina, et al.. (2007). FGF‐21/FGF‐21 receptor interaction and activation is determined by βKlotho. Journal of Cellular Physiology. 215(1). 1–7. 284 indexed citations

16.

Hui, Yu‐Hua, et al.. (2007). Pharmacokinetic comparisons of tail-bleeding with cannula- or retro-orbital bleeding techniques in rats using six marketed drugs. Journal of Pharmacological and Toxicological Methods. 56(2). 256–264. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact